Efruxifermin in patients with metabolic dysfunction-associated steatohepatitis: A GRADE-assessed systematic review and meta-analysis

Figure 1  Preferred Reporting Items for Systematic Reviews and Meta-Analyses chart of included studies.

Figure 2 Forest plot of outcomes. A: Achieving at least one stage of improvement in fibrosis without worsening of metabolic-associated steatohepatitis; B: Metabolic-associated steatohepatitis resolution without worsening fibrosis; C: At least a two-point improvement in the non-alcoholic fatty liver disease activity score with no worsening of fibrosis; D: Normalized liver fat; E: Enhanced liver fibrosis test score; F: Liver stiffness measurement score. CI: Confidence interval.

Figure 3 Forest plot of outcomes. A: Change in alanine aminotransferase; B: Change in aspartate aminotransferase; C: Percentage change in adiponectin; D: High-density lipoprotein cholesterol; E: Low-density lipoprotein cholesterol; F: Triglycerides; G: Homeostatic model assessment index. CI: Confidence interval.

Figure 4 Forest plot of outcomes. A: Serious adverse events; B: Adverse events leading to discontinuation; C: Nausea; D: Diarrhea; E: Injection site reaction. CI: Confidence interval.